jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies...
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..
.
see all results matching 'mub'
.
three other countries � spain, czech republic, and slovakia � had also been warned by the eu, but devised sufficient air management plans within the requested time frame..